This article is general educational content from a physician-led clinic. It does not replace a personal consultation, diagnosis, or medical advice. Candidacy, product choice, dosing, timing, risks, and results vary by patient. If symptoms feel severe, sudden, or unsafe to wait on after a treatment, seek urgent or emergency care; for emergencies, call 911.
Quick answer: how semaglutide and tirzepatide compare
If you are comparing semaglutide vs. tirzepatide for weight loss near Lancaster, CA, here is the short version. Both are prescription injectable medications used for chronic weight management, alongside nutrition and activity changes, when a physician decides they are appropriate. Semaglutide is the active ingredient in Wegovy® (and in Ozempic®, which is approved for type 2 diabetes). Tirzepatide is the active ingredient in Zepbound® (and in Mounjaro® for type 2 diabetes). In a 72-week head-to-head clinical trial called SURMOUNT-5, the group taking tirzepatide lost more weight on average than the group taking semaglutide. That is a study result describing groups of participants — it is not a promise of any individual outcome, and the right choice for a specific person depends on a medical evaluation. This article is general educational content, not medical advice, a diagnosis, a quote, or a treatment plan.
- Semaglutide = Wegovy® (weight management) / Ozempic® (type 2 diabetes).
- Tirzepatide = Zepbound® (weight management) / Mounjaro® (type 2 diabetes).
- Both are prescription injections used with diet and activity changes when appropriate.
- Trial averages describe study groups, not guaranteed personal results.
How they work: one hormone pathway vs. two
The main mechanical difference is how many hormone pathways each medication acts on. Semaglutide is a GLP-1 receptor agonist — it works on a single pathway (GLP-1) that influences appetite, fullness, and how the stomach empties. Tirzepatide is a dual agonist — it acts on two pathways, GIP and GLP-1. Researchers believe this dual action is part of why tirzepatide showed larger average weight loss in head-to-head research. Both medications are started low and increased slowly, and both are used as part of a broader plan rather than on their own.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Weight-management brand | Wegovy® | Zepbound® |
| Diabetes brand | Ozempic® | Mounjaro® |
| Hormone pathways | GLP-1 (one) | GIP + GLP-1 (two) |
| Form | Weekly injection | Weekly injection |
| Used with | Diet and activity changes | Diet and activity changes |
Reported results: what the head-to-head trial found
The most direct comparison so far is SURMOUNT-5, a 72-week randomized trial that compared tirzepatide and semaglutide for weight management in adults with obesity (or overweight with a weight-related condition) who did not have diabetes. In that trial, the tirzepatide group lost about 20% of body weight on average, while the semaglutide group lost about 14% on average, and a larger share of the tirzepatide group reached at least 25% weight loss. Those are average results across study participants over more than a year — individual results vary with the dose reached, how consistently the medication is taken, nutrition, activity, and other health factors. Trial data is useful for understanding general differences, but it does not predict what any one patient will experience.
- SURMOUNT-5 was a 72-week head-to-head trial in adults without diabetes.
- Average weight loss was higher in the tirzepatide group than the semaglutide group.
- Averages describe groups; they are not a guarantee for an individual.
- A physician reviews whether either medication fits your situation.
Side effects: similar categories, slightly different patterns
For both medications, the most commonly reported side effects are gastrointestinal. These tend to be most noticeable while the dose is being increased and often ease over time as the body adjusts. Reported patterns differ a little between the two, and serious risks, warnings, and contraindications exist for both — which is why the full prescribing information and your personal risk factors should be reviewed with a physician before starting, not after.
| Side-effect pattern | Semaglutide | Tirzepatide |
|---|---|---|
| More commonly reported | Nausea, constipation | Diarrhea, less nausea reported |
| When side effects peak | During dose increases | During dose increases |
| General trend over time | Often ease as the body adjusts | Often ease as the body adjusts |
| Serious risks | Reviewed in FDA labeling | Reviewed in FDA labeling |
Cost: why there is no single number
Cost is one of the most-searched questions, and the honest answer is that it varies widely. Out-of-pocket cost depends on the specific medication and dose, whether you have insurance, manufacturer savings or self-pay programs, and the pharmacy. Consumer drug-pricing guides describe 2026 brand self-pay costs commonly in roughly the $350 to $700 per month range, with insurance coverage or manufacturer programs able to lower it substantially for people who qualify. Compounded versions are sometimes advertised at lower prices, but the FDA has raised safety concerns about compounded semaglutide products sold outside the approved supply chain. These are national figures reported by others, not a KMHCS price — KMHCS does not sell these medications, so access, coverage, and cost questions are reviewed individually during consultation rather than quoted online.
- Price depends on the medication, dose, insurance, savings programs, and pharmacy.
- Insurance or manufacturer programs can lower cost for those who qualify.
- Compounded versions may be cheaper but carry FDA safety concerns.
- Bring your insurance details to a consultation to review real access and cost.
Who qualifies: candidacy is decided in a medical evaluation
FDA labeling for the weight-management versions generally describes adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. BMI is only a screening starting point. Whether a specific medication is appropriate for you also depends on your full medical history, current medications, pregnancy status, personal and family medical history, possible contraindications, and the prescribing information for the medication being discussed. Some people should not take these medications at all. A physician reviews all of this and decides whether medication should be considered, delayed, or replaced with another plan.
- General BMI guideposts: 30+, or 27+ with a weight-related condition.
- Full medical history, medications, and contraindications also matter.
- Some people are not candidates — that is determined by a physician.
- Pregnancy, certain personal or family history, and other factors affect eligibility.
How fast, and what about stopping?
Both medications are started at a low dose and increased gradually over weeks, which is meant to reduce side effects, so changes are typically gradual rather than immediate — the trial results above were measured over more than a year. Just as important is the long-term picture: research and FDA labeling indicate that many people regain weight after stopping GLP-1-based medications. For that reason these are usually discussed as part of a longer-term plan that pairs medication decisions with nutrition, activity, monitoring, and follow-up, rather than as a quick fix. Any decision to start, continue, adjust, or stop should be made with a physician.
How KMHCS approaches medical weight loss in Lancaster
At Kat Motlagh's Health Clinics in Lancaster, serving Palmdale and the wider Antelope Valley, medical weight loss is the medication-review side of weight management and is physician-led. A consultation reviews BMI, weight-related conditions, medication history, contraindications, labs when appropriate, side-effect and monitoring questions, insurance or self-pay and outside-pharmacy access, and long-term maintenance planning. Semaglutide (Wegovy®) or tirzepatide (Zepbound®) may be reviewed when clinically appropriate, but medication is optional, prescriptions are filled through outside pharmacies when appropriate, and no specific outcome is promised. If you are weighing these options, a consultation is the place to compare them against your own health history and goals.
Frequently asked questions
- Which is better for weight loss, semaglutide or tirzepatide?
- In a 72-week head-to-head trial (SURMOUNT-5), people taking tirzepatide lost more weight on average than people taking semaglutide. That trial result describes a study population, not any one patient. The medication that fits an individual depends on medical history, other conditions, side-effect tolerance, access and cost, and a physician's evaluation — which is why candidacy is decided in consultation, not by a headline.
- What is the difference between semaglutide and tirzepatide?
- Semaglutide (sold as Wegovy® for weight management and Ozempic® for type 2 diabetes) acts on one hormone pathway, GLP-1. Tirzepatide (sold as Zepbound® for weight management and Mounjaro® for type 2 diabetes) acts on two pathways, GIP and GLP-1. Both are prescription injections used alongside diet and activity changes when clinically appropriate.
- What are the side effects of semaglutide and tirzepatide?
- The most commonly reported side effects for both are gastrointestinal — nausea, diarrhea, constipation, and stomach discomfort — and they tend to be strongest while the dose is being increased and often ease over time. Reported patterns differ slightly (semaglutide is more often linked with nausea and constipation; tirzepatide more often with diarrhea). Serious risks and contraindications exist, so side effects, warnings, and monitoring should be reviewed with a physician before starting.
- How much do semaglutide and tirzepatide cost per month?
- Cost varies widely by medication, dose, insurance, manufacturer savings programs, and pharmacy. Consumer drug-pricing guides describe 2026 brand self-pay costs commonly in roughly the $350 to $700 per month range depending on the medication and dose, while insurance or manufacturer programs can lower out-of-pocket cost substantially — for some patients to little or nothing. Compounded versions are sometimes cheaper but carry FDA safety concerns. These are national figures reported by others, not a KMHCS price; KMHCS does not sell these medications, and prescriptions are filled through outside pharmacies when appropriate.
- Who qualifies for semaglutide or tirzepatide?
- FDA labeling for the weight-management versions generally describes adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. Eligibility for a specific person also depends on full medical history, current medications, pregnancy status, contraindications, and the prescribing information for the medication being discussed. A physician determines candidacy after evaluation.
- How fast does weight loss happen on these medications?
- These medications are started at a low dose and increased gradually over weeks to reduce side effects, so changes are typically gradual rather than immediate, with study results measured over many months. Individual response varies with starting point, dose, adherence, nutrition, activity, and other health factors.
- What happens if I stop taking the medication?
- Research and FDA labeling indicate that many people regain weight after stopping GLP-1-based medications, which is why these are generally discussed as long-term treatments paired with nutrition, activity, and follow-up planning rather than short courses. Any decision to start, continue, or stop should be made with a physician.
- Do you offer semaglutide or tirzepatide in Lancaster?
- KMHCS offers physician-led medical weight-loss consultations in Lancaster, serving Palmdale and the Antelope Valley. Semaglutide (Wegovy®) or tirzepatide (Zepbound®) may be reviewed when clinically appropriate after a physician evaluates BMI, weight-related conditions, medical history, contraindications, and access. Medication is optional and only considered when appropriate.
Sources and Further Reading
- New England Journal of Medicine: SURMOUNT-5 (tirzepatide vs. semaglutide) (opens in new tab): Peer-reviewed publication of the 72-week head-to-head SURMOUNT-5 trial comparing tirzepatide and semaglutide for weight management in adults with obesity who did not have diabetes.
- NIDDK: Prescription Medications to Treat Overweight & Obesity (opens in new tab): National Institute of Diabetes and Digestive and Kidney Diseases overview of FDA-approved weight-management medications, how they work, candidacy, and considerations.
- Mayo Clinic: Prescription weight-loss drugs (opens in new tab): General medical overview of prescription weight-loss medications, who they may be appropriate for, expected results, and possible side effects.
- FDA: Medications containing semaglutide marketed for type 2 diabetes or weight loss (opens in new tab): FDA information on semaglutide medications, including safety concerns related to compounded versions sold outside the approved supply chain.
- NHLBI: Calculate your body mass index (BMI) (opens in new tab): National Heart, Lung, and Blood Institute reference for body mass index, a common screening measure used in weight-management eligibility discussions.